Abstract

Obesity has become a major threat to health worldwide. The prevalence of obesity is rapidly increasing, so much so that the World Health Organization has declared obesity as a global epidemic. Obesity is associated with multiple health problems, including venous thromboembolism and atrial fibrillation, both of which are treated with anticoagulation. However, obesity and treatments for obesity such as bariatric surgery can influence absorption, excretion, pharmacokinetics, and pharmacodynamics of various anticoagulants. This results in uncertainty regarding the best antithrombotic strategies in this population, particularly in the morbidly obese. In the recent years, several studies have attempted to investigate anticoagulation use in this population and provided more insight. Herein, we present 4 cases of anticoagulant use in the obese to illustrate the common challenges faced by clinicians and discuss our approach. Whenever possible, we provide a review of the literature and base our recommendations on the best available evidence.

REFERENCES

REFERENCES
1.
National Center for Health Statistics (NCHS)
. National Health and Nutrition Examination Survey: NCHS Fact Sheet.
Hyattsville, MD
:
NCHS
;
2017
.
2.
Statistics Canada
.
Obesity in Canadian Adults
,
2016
and 2017. https://www150.statcan.gc.ca/n1/pub/11-627-m/11-627-m2018033-eng.htm. Accessed 20 October 2019.
3.
World Health Organization
,
Obesity and overweight
;
2018
. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 23 October 2019.
4.
Ward
ZJ
,
Bleich
SN
,
Cradock
AL
, et al
.
Projected U.S. state-level prevalence of adult obesity and severe obesity
.
N Engl J Med
.
2019
;
381
(
25
):
2440
-
2450
.
5.
Pomp
ER
,
le Cessie
S
,
Rosendaal
FR
,
Doggen
CJ
.
Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations
.
Br J Haematol
.
2007
;
139
(
2
):
289
-
296
.
6.
Rosito
GA
,
D’Agostino
RB
,
Massaro
J
, et al
.
Association between obesity and a prothrombotic state: the Framingham Offspring Study
.
Thromb Haemost
.
2004
;
91
(
4
):
683
-
689
.
7.
Morange
PE
,
Alessi
MC
.
Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology
.
Thromb Haemost
.
2013
;
110
(
4
):
669
-
680
.
8.
Hunt
BJ
.
Hemostasis at extremes of body weight
.
Semin Thromb Hemost
.
2018
;
44
(
7
):
632
-
639
.
9.
Eichinger
S
,
Hron
G
,
Bialonczyk
C
, et al
.
Overweight, obesity, and the risk of recurrent venous thromboembolism
.
Arch Intern Med
.
2008
;
168
(
15
):
1678
-
1683
.
10.
Rodger
MA
,
Kahn
SR
,
Wells
PS
, et al
.
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy
.
CMAJ
.
2008
;
179
(
5
):
417
-
426
.
11.
Rodger
MA
,
Le Gal
G
,
Anderson
DR
, et al;
REVERSE II Study Investigators
.
Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study
.
BMJ
.
2017
;
356
:
j1065
.
12.
Wanahita
N
,
Messerli
FH
,
Bangalore
S
,
Gami
AS
,
Somers
VK
,
Steinberg
JS
.
Atrial fibrillation and obesity--results of a meta-analysis
.
Am Heart J
.
2008
;
155
(
2
):
310
-
315
.
13.
Menezes
AR
,
Lavie
CJ
,
De Schutter
A
, et al
.
Lifestyle modification in the prevention and treatment of atrial fibrillation
.
Prog Cardiovasc Dis
.
2015
;
58
(
2
):
117
-
125
.
14.
Targher
G
,
Byrne
CD
.
Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications
.
Semin Thromb Hemost
.
2013
;
39
(
2
):
214
-
228
.
15.
Martin
KA
,
Lee
CR
,
Farrell
TM
,
Moll
S
.
Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance
.
Am J Med
.
2017
;
130
(
5
):
517
-
524
.
16.
Takahashi
H
,
Wilkinson
GR
,
Nutescu
EA
, et al
.
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
.
Pharmacogenet Genomics
.
2006
;
16
(
2
):
101
-
110
.
17.
Kearon
C
,
Akl
EA
,
Ornelas
J
, et al
.
Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report
.
Chest
.
2016
;
149
(
2
):
315
-
352
.
18.
Lip
GYH
,
Banerjee
A
,
Boriani
G
, et al
.
Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report
.
Chest
.
2018
;
154
(
5
):
1121
-
1201
.
19.
Martin
K
,
Beyer-Westendorf
J
,
Davidson
BL
,
Huisman
MV
,
Sandset
PM
,
Moll
S
.
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
.
J Thromb Haemost
.
2016
;
14
(
6
):
1308
-
1313
.
20.
Kubitza
D
,
Becka
M
,
Zuehlsdorf
M
,
Mueck
W
.
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
.
J Clin Pharmacol
.
2007
;
47
(
2
):
218
-
226
.
21.
Upreti
VV
,
Wang
J
,
Barrett
YC
, et al
.
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
.
Br J Clin Pharmacol
.
2013
;
76
(
6
):
908
-
916
.
22.
Reilly
PA
,
Lehr
T
,
Haertter
S
, et al;
RE-LY Investigators
.
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
.
J Am Coll Cardiol
.
2014
;
63
(
4
):
321
-
328
.
23.
Piran
S
,
Traquair
H
,
Chan
N
,
Bhagirath
V
,
Schulman
S
.
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study
.
Res Pract Thromb Haemost
.
2018
;
2
(
4
):
684
-
688
.
24.
Wasan
SM
,
Feland
N
,
Grant
R
,
Aston
CE
.
Validation of apixaban anti-factor Xa assay and impact of body weight
.
Thromb Res
.
2019
;
182
:
51
-
55
.
25.
Boriani
G
,
Ruff
CT
,
Kuder
JF
, et al
.
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
.
Eur Heart J
.
2019
;
40
(
19
):
1541
-
1550
.
26.
Barsam
SJ
,
Patel
JP
,
Roberts
LN
, et al
.
The impact of body weight on rivaroxaban pharmacokinetics
.
Res Pract Thromb Haemost
.
2017
;
1
(
2
):
180
-
187
.
27.
Schulman
S
,
Kakkar
AK
,
Goldhaber
SZ
, et al;
RE-COVER II Trial Investigators
.
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis
.
Circulation
.
2014
;
129
(
7
):
764
-
772
.
28.
Bauersachs
R
,
Berkowitz
SD
,
Brenner
B
, et al;
EINSTEIN Investigators
.
Oral rivaroxaban for symptomatic venous thromboembolism
.
N Engl J Med
.
2010
;
363
(
26
):
2499
-
2510
.
29.
Büller
HR
,
Prins
MH
,
Lensin
AW
, et al;
EINSTEIN–PE Investigators
.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
.
N Engl J Med
.
2012
;
366
(
14
):
1287
-
1297
.
30.
Agnelli
G
,
Buller
HR
,
Cohen
A
, et al;
AMPLIFY Investigators
.
Oral apixaban for the treatment of acute venous thromboembolism
.
N Engl J Med
.
2013
;
369
(
9
):
799
-
808
.
31.
Büller
HR
,
Décousus
H
,
Grosso
MA
, et al;
Hokusai-VTE Investigators
.
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
.
N Engl J Med
.
2013
;
369
(
15
):
1406
-
1415
.
32.
Di Minno
MN
,
Lupoli
R
,
Di Minno
A
,
Ambrosino
P
,
Scalera
A
,
Dentali
F
.
Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials
.
Ann Med
.
2015
;
47
(
1
):
61
-
68
.
33.
Boonyawat
K
,
Caron
F
,
Li
A
, et al
.
Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis
.
J Thromb Haemost
.
2017
;
15
(
7
):
1322
-
1333
.
34.
Di Nisio
M
,
Vedovati
MC
,
Riera-Mestre
A
, et al
.
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies
.
Thromb Haemost
.
2016
;
116
(
4
):
739
-
746
.
35.
Hohnloser
SH
,
Fudim
M
,
Alexander
JH
, et al
.
Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight
.
Circulation
.
2019
;
139
(
20
):
2292
-
2300
.
36.
Ezekowitz
ME
,
Parise
H
,
Connolly
SJ
, et al
.
The use of dabigatran according to body mass index: the RE-LY experience [abstract]
.
Congress of the European-Society-of-Cardiology (ESC); 30 August to 3 September 2014; Barcelona, Spain
.
37.
Tittl
L
,
Endig
S
,
Marten
S
,
Reitter
A
,
Beyer-Westendorf
I
,
Beyer-Westendorf
J
.
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119)
.
Int J Cardiol
.
2018
;
262
:
85
-
91
.
38.
Arachchillage
D
,
Reynolds
R
,
Devey
T
,
Maclean
R
,
Kitchen
S
,
van Veen
JJ
.
Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience
.
Thromb Res
.
2016
;
147
:
32
-
35
.
39.
Aloi
KG
,
Fierro
JJ
,
Stein
BJ
,
Lynch
SM
,
Shapiro
RJ
.
Investigation of direct-acting oral anticoagulants and the incidence of venous thromboembolism in patients weighing ≥120 kg compared to patients weighing <120 kg [published online ahead of print 29 June 2019]
.
J Pharm Pract
.
doi:10.1177/0897190019854578
.
40.
Netley
J
,
Howard
K
,
Wilson
W
.
Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review
.
J Thromb Thrombolysis
.
2019
;
48
(
3
):
359
-
365
.
41.
Kido
K
,
Ngorsuraches
S
.
Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation
.
Ann Pharmacother
.
2019
;
53
(
2
):
165
-
170
.
42.
Kushnir
M
,
Choi
Y
,
Eisenberg
R
, et al
.
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
.
Lancet Haematol
.
2019
;
6
(
7
):
e359
-
e365
.
43.
Kalani
C
,
Awudi
E
,
Alexander
T
,
Udeani
G
,
Surani
S
.
Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients
.
Hosp Pract (1995)
.
2019
;
47
(
4
):
181
-
185
.
44.
Perales
IJ
,
San Agustin
K
,
DeAngelo
J
,
Campbell
AM
.
Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight [published online ahead of print 31 October 2019]
.
Ann Pharmacother
.
doi:10.1177/1060028019886092
.
45.
Peterson
ED
,
Ashton
V
,
Chen
YW
,
Wu
B
,
Spyropoulos
AC
.
Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
.
Am Heart J
.
2019
;
212
:
113
-
119
.
46.
Spyropoulos
AC
,
Ashton
V
,
Chen
YW
,
Wu
B
,
Peterson
ED
.
Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs
.
Thromb Res
.
2019
;
182
:
159
-
166
.
47.
English
WJ
,
DeMaria
EJ
,
Brethauer
SA
,
Mattar
SG
,
Rosenthal
RJ
,
Morton
JM
.
American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016
.
Surg Obes Relat Dis
.
2018
;
14
(
3
):
259
-
263
.
48.
Hakeam
HA
,
Al-Sanea
N
.
Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)
.
J Thromb Thrombolysis
.
2017
;
43
(
3
):
343
-
351
.
49.
Kröll
D
,
Stirnimann
G
,
Vogt
A
, et al
.
Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery
.
Br J Clin Pharmacol
.
2017
;
83
(
7
):
1466
-
1475
.
50.
Kröll
D
,
Nett
PC
,
Borbély
YM
, et al
.
The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study
.
Surg Obes Relat Dis
.
2018
;
14
(
12
):
1890
-
1896
.
51.
Rottenstreich
A
,
Barkai
A
,
Arad
A
,
Raccah
BH
,
Kalish
Y
.
The effect of bariatric surgery on direct-acting oral anticoagulant drug levels
.
Thromb Res
.
2018
;
163
:
190
-
195
.
52.
Kubitza
D
,
Becka
M
,
Zuehlsdorf
M
,
Mueck
W
.
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
.
J Clin Pharmacol
.
2006
;
46
(
5
):
549
-
558
.
53.
Bourne
R
,
Mukhi
S
,
Zhu
N
,
Keresteci
M
,
Marin
M
.
Role of obesity on the risk for total hip or knee arthroplasty
.
Clin Orthop Relat Res
.
2007
;
465
(
465
):
185
-
188
.
54.
Kapoor
A
,
Ellis
A
,
Shaffer
N
, et al
.
Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis
.
J Thromb Haemost
.
2017
;
15
(
2
):
284
-
294
.
55.
Eriksson
BI
,
Dahl
OE
,
Feuring
M
, et al
.
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis
.
Thromb Res
.
2012
;
130
(
5
):
818
-
820
.
56.
Friedman
RJ
,
Hess
S
,
Berkowitz
SD
,
Homering
M
.
Complication rates after hip or knee arthroplasty in morbidly obese patients
.
Clin Orthop Relat Res
.
2013
;
471
(
10
):
3358
-
3366
.
57.
Pineo
GF
,
Gallus
AS
,
Raskob
GE
, et al
.
Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups
.
J Thromb Haemost
.
2013
;
11
(
3
):
444
-
451
.
58.
Pathak
R
,
Karmacharya
P
,
Giri
S
, et al
.
Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients
.
Blood Coagul Fibrinolysis
.
2015
;
26
(
6
):
635
-
642
.
You do not currently have access to this content.